Revivo Therapeutics is addressing the major medical needs of concussion and cognitive decline with a new class of small molecules.

Our lead compound has an excellent safety profile and has been shown to cross the blood-brain barrier.
It is orally active. The Company is preparing clinical supply for Phase-ll trials.

This site is under development as we advance the frontiers of discovery. Check back soon.